CoreLine Soft Co

CoreLine Soft Co R&D / Revenue

The R&D to Revenue Ratio of CoreLine Soft Co (384470.KQ) as of Nov 5, 2026 is 47.87 %. In the previous year, R&D to Revenue Ratio was 68.38 % — a change of -30.00% (lower).

R&D / Revenue

47.87 %

YoY

-30.00%

Last updated:

R&D to Revenue Ratio of CoreLine Soft Co is 2025 47.87 % . R&D to Revenue Ratio of CoreLine Soft Co was 2024 68.38 % . It decreases by -30.00% lower compared to the previous year.

The CoreLine Soft Co R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2020
30.75 KRW
Jan 1, 2021
88.98 KRW
Jan 1, 2022
51.01 KRW
Jan 1, 2023
48.33 KRW
Jan 1, 2024
68.38 KRW
Jan 1, 2025
47.87 KRW
The CoreLine Soft Co R&D / Revenue history
YEARR&D / RevenueYoY
47.87 %-30.00%
68.38 %+41.49%
48.33 %-5.26%
51.01 %-42.66%
88.98 %+189.32%
30.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CoreLine Soft Co Stock analysis

What does CoreLine Soft Co do? CoreLine Soft Co Ltd develops and supplies AI-based medical image analysis software for healthcare professionals. The company's main products analyze CT images of the chest, head, and neck to assist in diagnosis and support treatment and research. The firm targets medical staff in hospitals and research institutions who require advanced diagnostic tools. CoreLine Soft generates revenue through the sale of its medical software solutions to healthcare providers and research organizations. The company operates in the Health Care Technology industry with a focus on AI-driven medical imaging. CoreLine Soft's products are designed to enhance diagnostic accuracy and streamline treatment planning for medical professionals. Revenue is derived from licensing agreements with healthcare facilities and research entities that integrate the software into their diagnostic workflows. CoreLine Soft Co Ltd is a Korea-based company headquartered in Seoul. The firm's primary business model revolves around the development and commercialization of AI-based medical software. The company's revenue streams come from direct sales of its CT image analysis solutions to hospitals and research institutions seeking to improve diagnostic efficiency and patient outcomes. CoreLine Soft Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CoreLine Soft Co stock

R&D to Revenue Ratio of CoreLine Soft Co is 47.87 % in 2025.

R&D to Revenue Ratio of CoreLine Soft Co changed from 68.38 % to 47.87 %, representing a -30.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio CoreLine Soft Co since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's CoreLine Soft Co with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CoreLine Soft Co

All Key Metrics — CoreLine Soft Co